During the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, researchers presented data from the Phase 2 OVARIO clinical trial. According to Cancer Network, the trial evaluated…
Dr. Oliver Dorigo of the Stanford University Medical Center was the medical source for an article featured in Oncology. Dr. Dorigo explained that if a woman with ovarian cancer has…
According to a story from Targeted Oncology, Dr. Bradley Monk talked about the importance of molecular testing in determining the treatment course for ovarian cancer at the Targeted Oncology Case…
According to a story from Cancer Network, the European Commission has recently approved a two-part combination treatment for advanced, homologous recombination deficiency (HRD)-positive ovarian cancer. This first-line maintenance treatment consists…
Each year, around 14,000 U.S. deaths are attributed to ovarian cancer. Yet researchers have historically struggled to find an exact cause of the cancer, or to understand exactly how…
Lynparaza is back in the news again, but this time, according to Cure Today, the FDA approved the drug in combination with Avastin for advanced ovarian cancer to prevent progression…
According to a press release from PR Newswire and GuruFocus, drug discovery and development company Sutro Biopharma received promising phase 1 clinical data for their drug therapy STRO-002. Their Phase…
Recently, says Medical XPress, an international research team discovered that the drug therapy 2-deoxy D-glucose can slow cell growth. In patients with ovarian cancer, the drug can halt the growth…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
